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Abstract
Background: Molecular studies of breast cancer revealed biological heterogeneity of the disease and opened new
perspectives for personalized therapy. While multiple gene expression-based systems have been developed, current
clinical practice is largely based upon conventional clinical and pathologic criteria. This gap may be filled by
development of combined multi-IHC indices to characterize biological and clinical behaviour of the tumours.
Digital image analysis (DA) with multivariate statistics of the data opens new opportunities in this field.
Methods: Tissue microarrays of 109 patients with breast ductal carcinoma were stained for a set of 10 IHC markers
(ER, PR, HER2, Ki67, AR, BCL2, HIF-1a, SATB1, p53, and p16). Aperio imaging platform with the Genie, Nuclear and
Membrane algorithms were used for the DA. Factor analysis of the DA data was performed in the whole group
and hormone receptor (HR) positive subgroup of the patients (n = 85).
Results: Major factor potentially reflecting aggressive disease behaviour (i-Grade) was extracted, characterized by
opposite loadings of ER/PR/AR/BCL2 and Ki67/HIF-1a. The i-Grade factor scores revealed bimodal distribution and
were strongly associated with higher Nottingham histological grade (G) and more aggressive intrinsic subtypes. In
HR-positive tumours, the aggressiveness of the tumour was best defined by positive Ki67 and negative ER loadings.
High Ki67/ER factor scores were strongly associated with the higher G and Luminal B types, but also were detected
in a set of G1 and Luminal A cases, potentially indicating high risk patients in these categories. Inverse relation
between HER2 and PR expression was found in the HR-positive tumours pointing at differential information
conveyed by the ER and PR expression. SATB1 along with HIF-1a reflected the second major factor of variation in
our patients; in the HR-positive group they were inversely associated with the HR and BCL2 expression and
represented the major factor of variation. Finally, we confirmed high expression levels of p16 in Triple-negative
tumours.
Conclusion: Factor analysis of multiple IHC biomarkers measured by automated DA is an efficient exploratory tool
clarifying complex interdependencies in the breast ductal carcinoma IHC profiles and informative value of single
IHC markers. Integrated IHC indices may provide additional risk stratifications for the currently used grading
systems and prove to be useful in clinical outcome studies.
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The last decade was marked by intense molecular stu-
dies of breast cancer recognizing significant biological
heterogeneity of the disease and leading to definition of
the molecular types. This has opened new perspectives
for personalized therapy and development of multiple
gene expression-based systems to prognosticate the dis-
ease outcomes and assist in therapeutic decisions [1,2].
Despite proven clinical utility of the systems, at least in
the context of some categories of breast cancer, they
remain relatively expensive, centralized and frequently
require fresh frozen tumour specimens.
Due to the limitations of the molecular systems, cur-
rent clinical practice of breast cancer therapy is largely
based upon conventional clinical and pathologic criteria,
including mainly tumour stage (T), lymph node involve-
ment (N), histological grade (G), expression of hormone
receptors (HR), and hyper-expression and amplification
of human epidermal growth factor receptor 2 (HER2) in
the tumour tissue [2,3]. The gap between the accumu-
lated knowledge on multiple molecular profiles of the
breast cancer and common clinical practice remains
open and in some way is compensated by intrinsic bio-
logical subtypes adopted by St Gallen in 2011 [4]. The
subtypes may be approximated using clinicopathological
rather than gene expression array criteria. Therapy
recommendations follow the subtype classification:
Luminal A disease generally requires only endocrine
therapy, which also forms part of the treatment of the
Luminal B subtype. Chemotherapy is considered for
most patients with Luminal B, HER2 positive, and Tri-
ple-negative (ductal) disease, with the addition of trastu-
zumab in HER2 positive disease [4]. Distinction between
the Luminal A and Luminal B subtypes is based on the
estimate of proliferative activity of the tumour, mea-
sured by the percentage of Ki67-positive tumour cells
[4,5] by immunohistochemistry (IHC).
Although the proposed approach provides a bridge
between the molecular types of the disease and clinical
practice, it is still largely based on semi-quantitative eva-
luation of estrogen receptor (ER), progesteron receptor
(PR), HER2, and Ki67 expression visualized by IHC. The
latter method is confined to an issue of defining and
then following cut-off values which leads to misclassifi-
cation of some patients, at least in borderline cases.
According to the currently accepted standards, the
reproducibility of the IHC tests is suboptimal, the con-
cordance between the methods and laboratories is below
expectations for good clinical practice [1]. The improve-
ment in this area could come from standardizing all
phases of the IHC (and HER2 FISH) tests [6,7] along
with application of image analysis tools to obtain more
accurate, reproducible and quantitative results [8,9]. In
addition, digital image analysis (DA) providing continu-
ous data of the IHC biomarker expression is an impor-
tant prerequisite to apply more powerful mathematical
analysis tools for tissue-based biomarker research.
In the view of urgent need to improve prognostic clas-
sifiers in breast cancer, efforts are being made to use a
combinatorial approach revealing new aspects of the dis-
ease and promising more reliable stratification of the
risk based on combined biomarkers rather than single
ones [10]. In essence, it corresponds to the multivariate
analysis approach used to develop multiple gene expres-
sion-based systems. It has been shown that similar infor-
mation can be obtained by a combination of relevant
IHC markers [11-14], including the heterogeneity of the
disease revealed by cluster analysis [15]. However, com-
bined IHC biomarkers proposed up-to-the-date are
mostly based on a combination of several biomarkers
evaluated qualitatively or semi-quantitatively. Although
clinical utility can be achieved already, it is important to
employ multivariate analysis methods to exploit broad
dynamic range of the IHC DA data. An important
exploratory step of the investigation is delivered by fac-
tor analysis, revealing independent factors of variation in
the data set of multiple IHC biomarkers. Multidimen-
sional data space reduction and extraction of latent
variability factors may uncover true biological meaning
and informative value of single biomarkers and provide
integrated factor scores as quantitative estimates of the
biological processes [16]. This may be the only right
approach since one biomarker can reflect several biolo-
gical processes and have different roles in different dis-
ease entities. Furthermore, most robust prognostic
factors are likely to come in a form of integrated meta-
markers derived by multivariate analysis of multimodal
data of various aspects (clinical, pathology, molecular,
imaging, etc.) of the disease [13].
In our study, we performed an automated image ana-
lysis on a set of 10 IHC markers, including the conven-
t i o n a lE R ,P R ,H E R 2 ,a n dK i 6 7a l o n gw i t hl e s s
investigated androgen receptor (AR), BCL2, HIF-1a,
SATB1, p53 and p16 on tissue microarrays (TMAs) of
109 patients with ductal carcinoma of the breast. We
present the potential of factor analysis of the IHC mar-
ker expression data set to reveal biologically and clini-
cally meaningful interdependencies of the breast cancer
immunophenotype.
Materials and methods
Study population and clinical methods
Tumour samples were prospectively collected from 203
patients with an invasive ductal carcinoma of the breast
treated at the Oncology Institute of Vilnius University
and investigated at the National Center of Pathology
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was obtained and documented in writing before study
entry. The study was approved by the Lithuanian
Bioethics Committee.
The TMAs were constructed from 10% buffered forma-
lin-fixed paraffin-embedded tissue blocks. One millimetre-
diameter cores were punched from tumour areas ran-
domly selected by pathologist (4 cores per patient), thus
producing 11 TMAs constructed using the tissue arraying
instrument (3DHISTECH, TMA Master, Budapest, Hun-
gary). Paraffin sections of the TMAs were cut for IHC (3
μm-thick) and HER2 FISH testing (4 μm-thick).
IHC was performed on the TMA sections using Ultra-
view DAB detection kit on Ventana BenchMark XT
staining system (Ventana Medical Systems, Tucson, Ari-
zona, USA) [17]. Immunohistochemistry for ER, PR,
HER2, AR, Ki67, p53, p16, BCL2, SATB1 and HIF-1a
was performed using the SP1, 1E2 and 4B5 (Ventana),
SP107 (Spring), MIB-1 (DAKO), DO-7 (Novocastra),
E6H4 (CINtec), 124 (DAKO), EPR3895 and EP1215Y
(Epitomics) antibodies, respectively. The protocols for
HER2 fluorescence in situ hybridization analysis were
used as described previously [17].
Digital images were captured using the Aperio Scan-
Scope XT Slide Scanner (Aperio Technologies, Vista,
CA, USA) under 20× objective magnification. All TMA
spots were evaluated on the monitor visually by the
pathologist (DD), providing semi-quantitative estimates
of the percentage of positive cells and excluding the
spots containing inadequate tumour sample or DCIS
from further analyses. The estimates were used for qual-
ity assurance of DA results and classification into intrin-
sic subtypes (see below).
Based on the visual pathologist’s evaluation of the ER,
PR, HER2 and Ki67 IHC results and HER2 FISH results
[17], the cases were classified into the intrinsic subtypes:
Luminal A (ER and/or PR positive, HER2 negative, Ki67
< 14%), Luminal B, HER2 negative (ER and/or PR posi-
tive, HER2 negative, Ki67 ≥ 14%), Luminal B, HER2
positive (ER and/or PR positive, any Ki67, HER2 over-
expressed or amplified), HER2 positive, non-luminal
(HER2 over-expressed or amplified, ER and PR absent),
Triple-negative (ER and PR absent, HER2 negative) [4].
Digital image analysis
The DA was performed on the same images as the
visual evaluation. Aperio Genie Classifier was trained to
recognize tumour tissue, stroma and background (glass).
The Genie classifier was then combined with Aperio
Membrane v9 and Aperio Nuclear v9 algorithms.
Respectively, positive tumour cell was defined at the
membrane completeness threshold of 50 or the thresh-
old of weak (1+) or higher nuclear staining. The percen-
tage of tumour cells with complete membranous (HER2
and BCL2) staining and positive nuclear (ER, PR, AR,
Ki67, p53, p16, SATB1 and HIF-1a) staining was used
for further analyses. The examples of IHC and DA ana-
lysis output images are presented in Figure 1. The data
from all adequate TMA spots were summarized (posi-
tive and total cells in the spots were summed, then the
percentage of positive cells calculated) into one estimate
per patient with a threshold of total number of tumour
cells per patient set at > 500. A total of 109 patients
with a complete set of 10 IHC markers remained for
multivariate analyses.
Statistical analysis
Summary statistics and distribution analyses were per-
formed with significance tests based on one-way ANOVA
and Bonferroni (Dunn) t Tests for pairwise comparisons.
Since distributions of HER2, Ki67, HIF-1a, SATB1, p53,
and p16 DA results revealed left asymmetry, logarithm-
transformed values were used for parametric statistics. For
the sake of readability, the prefix “log” is not used in the
text or graphs when referring to these markers.
Factor analysis on a DA data set of 10 IHC markers
was performed using factoring method of principal com-
ponent analysis. Five factors were retained based on the
threshold of the smallest eigenvalue of 0.85. General
orthomax rotation of the initial factors was performed.
Factor analyses were performed in two sets of patients:
the whole group of ductal carcinoma (n = 109) and HR-
positive ductal carcinoma (n = 85) including Luminal A,
B, and B HER2 positive tumours.
Pearson’s correlation was performed to test the pair-
wise linear relationships between the continuous vari-
ables as a preparatory step for factor analyses. Chi-
square test and Fisher’s exact test were used to estimate
significant associations in non-parametric statistics. Sta-
tistical significance level was set at p< 0.05. Statistical
analysis was performed with SAS 9.2 software.
Results
Patient and tumour characteristics
The patients’ age distribution, tumour stage (T), lymph
node status (N), and histological grade (G), based on the
Nottingham Grading System [18], are presented in the
T a b l e1 .S i n c et h ei n t r i n s i csubtypes were subdivided
based on the visual evaluation of the IHC images, the DA
results on ER, PR, HER2, and Ki67 do not strictly corre-
spond to the conventional cut-off values used for the
definition of intrinsic subtypes [4]. Pairwise correlations
between the IHC markers are presented in the Table 2.
Factor analysis of the immunophenotype of the ductal
carcinoma of the breast
Factor analysis was performed on 109 patients with a com-
plete set of 10 IHC markers: ER, PR, AR, HER2, BCL2,
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Page 3 of 16Ki67, HIF-1a, SATB1, p53, and p16. Rotated factor pat-
tern is presented in the Table 3. Altogether the five factors
explained 80% of the variance in the data set.
Factors 1 and 2 represented major portion of the var-
iance explained by the five factors extracted (43.9 and
15.7%, respectively). Factor loadings of the factors 1 and
2 are plotted on the Figure 2. The factor 1 is character-
ized by strong positive loadings of HR (ER, PR, AR) and
BCL2 as well as strong negative loadings of Ki67 and
HIF-1a. Based on the known biological and prognostic
information conveyed by these IHC markers in the con-
text of breast marker and their strong association to the
histological grade in our study (see below), this factor
pattern can be interpreted as representing a spectrum of
“the immunohistochemical grade” (i-Grade): from the
tumours with predominant expression of HR and BCL2
(i-Grade-Low) to the tumours with predominant expres-
sion of Ki67 and HIF-1a (i-Grade-High).
Factor 2 was characterized by strong positive loadings of
SATB1 and HIF-1a (factor loading 0.89 and 0.58, respec-
tively) and was labelled as “SATB1/HIF-1a” (Figure 2).
The distributions of the factor 1 and 2 scores are
plotted (Figure 3a) and represented in the corresponding
histograms (Figure 3b and 3c). The histograms reveal
bimodal distribution of the factor 1 (i-Grade) and nor-
mal distribution of the factor 2 (SATB1/HIF-1a)s c o r e s .
Accordingly, the heterogeneity of the patient group can
be noted in the scatter plot (Figure 3a). To test the asso-
ciations with clinical and pathologic features, the
patients were dichotomized into the i-Grade categories
“Low” (factor 1 score > -0.5) and “High” (factor 1 score
≤ -0.5); and the SATB1/HIF-1a expression categories
“Low” (factor 2 score ≤ 0) and High (factor 2 score > 0).
Factors 3, 4 and 5 altogether represented the remain-
ing 40.5% (14.6, 13.5, and 12.4%, respectively) of the var-
iance explained by the five factors extracted (Table 3).
The factors were characterized by positive loadings of
single biomarkers and named accordingly: factor 3
(HER2), factor 4 (p53), and factor 5 (p16). The corre-
sponding factor scores revealed normal distribution (not
shown). These factors were dichotomized at the cut-off
value of 0.
f e
c
b a
d
Figure 1 The examples of immunohistochemistry and digital analysis output images. Immunohistochemistry and corresponding digital
analysis outputs of SATB1 (a and b), HIF-1a (c and d), and BCL2 (e and f). The Nuclear algorithm (b and d) marks the positive cells with color
mask according staining intensity (0 - blue, 1+ - yellow, 2+ - orange, 3+ - red). The Membrane algorithm (f) marks the positive cells with
complete membranous staining with red outline.
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conventional categories of the ductal carcinoma of the
breast
We explored potential associations between the factor 1
and 2 score categories and the conventional characteris-
tics of the disease: the intrinsic subtype, histological
grade (G), tumour stage (T), node status (N), and age
group (Table 4).
The factor 1 (i-Grade) was associated with the intrinsic
subtypes (p< 0.0001): all cases of HER2-positive (n = 6)
and all but one (94%) Triple-negative carcinoma fell into
the i-Grade-High category. Significant proportion of Lumi-
nal B (26%) and Luminal B HER2 positive (40%) cases but
none of Luminal A type (n = 43) were i-Grade-High.
Association between the i-Grade and the G was highly
significant (p< 0.0001, Figure 4): all cases of G1 were
Table 1 Patient and tumour characteristics
Intrinsic subtype
Luminal A Luminal B Luminal B HER2+ HER2+ Triple-negative p
Age group n.s
Age < 55 year (n = 52) 17 (40) 14 (52) 8 (53) 1 (17) 12 (67)
Age > 55 year (n = 57) 26 (60) 13 (48) 7 (47) 5 (83) 6 (33)
Histological grade < 0.0001
1 16 (37) 2 (8) 1 (7) 0 (0) 0 (0)
2 26 (61) 6 (22) 6 (40) 3 (50) 3 (17)
3 1 (2) 19 (70) 8 (53) 3 (50) 15 (83)
T n.s.
1 28 (65) 13 (48) 8 (53) 3 (50) 6 (33)
2 15 (35) 14 (52) 7 (47) 3 (50) 12 (67)
N n.s.
0 27 (63) 13 (48) 8 (53) 4 (67) 14 (78)
1 16 (37) 14 (52) 7 (47) 2 (33) 4 (22)
% positive cells by immunohistochemistry
measured by digital image analysis (mean ± SD)*
ER 80 ± 13 62 ± 33 52 ± 26 2 ± 1 4 ± 7 < 0.0001
PR 53 ± 31 38 ± 36 19 ± 29 2 ± 2 3 ± 4 < 0.0001
AR 47 ± 20 32 ± 23 28 ± 21 33 ± 15 10 ± 15 < 0.0001
BCL2 56 ± 11 46 ± 24 33 ± 27 7 ± 6 18 ± 15 < 0.0001
HER2 7 ± 11 7 ± 12 37 ± 25 64 ± 19 1 ± 3 < 0.0001
Ki67 14 ± 7 40 ± 17 22 ± 12 31 ± 15 53 ± 16 < 0.0001
p53 13 ± 16 34 ± 32 19 ± 18 17 ± 26 44 ± 35 n.s.
p16 14 ± 8 14 ± 12 14 ± 7 10 ± 4 40 ± 21 < 0.0001
HIF-1a 9 ± 6 12 ± 10 12 ± 10 18 ± 13 18 ± 10 < 0.005
SATB1 12 ± 7 14 ± 10 13 ± 10 10 ± 4 19 ± 18 n.s.
* Statistical significance of variation between the groups tested by one-way ANOVA (logarithm-transformed values of HER2, Ki67, p53, p16, HIF-1a, SATB1 were
used for the analysis, however, original values are presented in the table)
Table 2 Pairwise correlations between the immunohistochemical markers of ductal carcinoma of the breast
ER PR AR BCL2 HER2 Ki67 p53 p16 HIF-1a SATB1
ER 1.0000
PR 0.5562 1.0000
AR 0.5651 0.6199 1.0000
BCL2 0.6950 0.5159 0.4403 1.0000
HER2 0.0148 -.2411 -.0097 -.1898 1.0000
Ki67 -.5022 -.3644 -.4497 -.3804 -.1313 1.0000
p53 -.1546 -.0204 -.0731 -.2154 0.0602 0.1930 1.0000
p16 -.2583 -.2016 -.1513 -.1058 -.0619 0.1363 0.0264 1.0000
HIF-1a -.4606 -.4763 -.5118 -.4665 0.0130 0.3136 0.0245 0.1499 1.0000
SATB1 -.2651 -.2065 -.3727 -.2572 -.0253 0.0877 0.1345 0.0749 0.5159 1.0000
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Page 5 of 16i-Grade-Low (n = 19) whereas G2 and G3 were increas-
ingly i-Grade-High (21%, and 58%, respectively). The i-
Grade was not significantly associated with T, N, or
patient age group.
Factor 3 (HER2) was associated with older age and
presented relevant associations with the intrinsic
subtypes (Table 4), however, significant proportion of
Luminal A and B and one Triple-negative case were in
the HER2-High category. This is related to the relatively
low HER2-High cut-off value (0) used for dichotomiza-
tion of the factor score.
Factor 5 (p16) was remarkable presenting with high
values in the majority (83%) of TN cases. Factor 2
(SATB1/HIF-1a) and factor 4 (p53) were not signifi-
cantly associated with any of the categories tested
(Table 4).
The IHC profile of the intrinsic subtypes was further
highlighted by one-way ANOVA with the factor scores
used as dependent variables. Summary of the profiles
is plotted on Figure 5. Significant (p< 0.0001) ANOVA
models were obtained for the factors 1, 3, and 5.
Remarkably, the (1) Luminal A, (2) Luminal B with
Luminal B HER+, and (3) HER2+ with the Triple-
negative tumours formed three distinct subgroups of
the factor 1 distribution (relevant pairwise comparisons
of the three groups were statistically significant). Fac-
tor 3 (HER2) distribution was concordant with the
Table 3 Rotated factor pattern of the immunothenotype
variation of ductal carcinoma of the breast
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5
ER 0.83941 -0.01623 0.06273 -0.10947 -0.13607
PR 0.78891 -0.03484 -0.28622 0.17900 -0.09682
AR 0.77439 -0.22905 0.06032 0.10351 0.00616
BCL2 0.76608 -0.06227 -0.21251 -0.21011 0.03420
HER2 -0.08421 -0.06469 0.93842 0.05171 -0.05224
Ki67 -0.70211 -0.23907 -0.38056 0.18840 -0.04474
p53 -0.11614 0.05720 0.03361 0.95603 0.00840
p16 -0.18339 0.01554 -0.04829 0.00668 0.97677
HIF-1a -0.61104 0.57686 -0.04245 -0.11539 0.02041
SATB1 -0.25600 0.89064 -0.03403 0.11291 0.00695
Figure 2 Rotated factor pattern in the patients with breast ductal carcinoma: loadings of the factors 1 and 2 plotted. The loadings of
the factor 1 (i-Grade) and factor 2 (SATB1/HIF-1a) plotted.
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Page 6 of 16definition of the intrinsic subtypes; although Luminal
A showed slightly higher values than Luminal B, the
pairwise comparison did not reveal significant differ-
ence. Factor 5 (p16) was remarkable for high values in
the TN tumours, significantly (p< 0.05) higher than in
all other intrinsic subtypes. Pairwise comparisons of
the p16 variance presented the same significant differ-
ences (Table 1).
3b
3c
3a
Figure 3 The distribution of the factor 1 and 2 scores in the patients with breast ductal carcinoma. a) scatter plot of the factor 1 and 2
scores; b) histogram of the factor 1 (i-Grade) scores; c) histogram of the factor 2 (SATB1/HIF-1a) scores.
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positive ductal carcinoma of the breast
To explore the immunophenotype interactions in the
group of HR-positive tumours, we performed factor ana-
lysis in 85 cases of Luminal A, Luminal B, and Luminal
B HER2 positive tumours (the analysis of 70 patients
with Luminal A and B only gave similar results and is
not presented here). The rotated factor pattern is pre-
sented in the Table 5, Factor 1 and 2 loadings are
plotted on Figures 6 and 7. Altogether the five factors
explained 77% of the variance in the data set.
The factor 1 (31.1% of variation) resembled the factor
2( S A T B 1 / H I F - 1 a) in the whole group of the patients,
however, the factor pattern was different: it was charac-
terized by strong positive loading of HIF-1a, identical to
that of SATB1, and by moderate negative loadings of
AR, ER, and BCL2. This pattern suggests inverse rela-
tion between SATB1 and HIF-1a co-expression and the
co-expression of AR, ER, and BCL2 in the subgroup of
HR-positive tumours. Since the biological meaning of
this interrelation is not clear, this factor is labelled
“SATB1/HIF-1a-AR/ER/BCL2”.
The factors 2 and 3 contributed a similar proportion
of variation (19.8 and 19.7%, respectively) to the data
set. Factor 2 was characterized by positive HER2 (0.87)
and negative PR (-0.68) loadings, while factor 3 - by
positive Ki67 (0.83) and negative ER (-0.60) loadings.
Respectively, these factors were labelled “HER2-PR” and
“Ki67-ER”.
Factors 4 (p53) and 5 (p16) resembled those already
identified in the whole group of patients and contribu-
ted 15.7 and 13.8% of variation, respectively.
All factor scores revealed a normal distribution (not
shown) and were dichotomized at the cut-off value of 0.
Associations between the factor scores and the
conventional categories of the HR-positive ductal
carcinoma of the breast
Factor 1 (SATB1/HIF-1a-AR/ER/BCL2) score categories
were not associated with the patient’s age group, T, N,
G, or intrinsic subtype (Table 6). Factor 2 (HER2-PR)
score High category was associated with the older
patients’ age group (p< 0.002) and intrinsic subtype (p
<0.05).
Associations of the factor 3 (Ki67-ER) score categories
closely resembled those of the factor 1 (i-Grade) in the
whole group of patients: high scores were increasing
with the histological grade (p< 0.0001, Figure 8) and
more frequently found in Luminal B subtypes (p
<0.0001). Remarkably, some Ki67-ER-High tumours
were detected in both G1 (3/19, 16%) and Luminal A
(9/43, 21%) categories.
Discussion
Our study proves that important biological interdepen-
dencies can be detected at the level of tumour tissue
immunophenotype based on the multivariate analysis of
DA data. In a cohort of 109 patients with ductal
Table 4 Associations between the factor 1 and 2 scores and the conventional categories of the ductal carcinoma of
the breast
n i-Grade-High SATB1/HIF-1a-High HER2-High p53-High p16-High
Number of patients 109
Age group n.s. n.s. p< 0.03 p< 0.003 n.s.
Age < 55 year 52 19 (37) 28 (54) 20 (38) 39 (75) 28 (54)
Age > 55 year 57 17 (30) 29 (51) 34 (60) 27 (47) 30 (53)
Histological grade p< 0.00001 n.s. n.s. n.s. n.s.
1 19 0 (0) 12 (63) 10 (53) 7 (37) 12 (63)
2 44 9 (21) 26 (59) 27 (61) 30 (68) 22 (50)
3 46 27 (59) 19 (41) 17 (37) 29 (63) 24 (52)
T n.s. n.s. n.s. n.s. n.s.
1 58 16 (28) 31 (53) 33 (57) 37 (64) 27 (47)
2 51 20 (44) 26 (51) 21 (41) 29 (57) 31 (61)
N n.s. n.s. n.s. n.s. n.s.
0 66 25 (38) 36 (55) 30 (45) 40 (61) 35 (53)
1 43 11 (26) 21 (49) 24 (56) 26 (60) 23 (53)
Intrinsic subtype p< 0.0001 n.s. p< 0.00001 n.s. p< 0.002
Luminal A 43 0 (0) 29 (67) 25 (58) 23 (53) 26 (60)
Luminal B 27 7 (26) 10 (37) 10 (37) 19 (70) 8 (30)
Luminal B HER2+ 15 6 (40) 7 (47) 12 (80) 10 (67) 8 (53)
HER2+ 6 6 (100) 2 (33) 6 (100) 2 (33) 1 (17)
Triple-negative 18 17 (94) 9 (50) 1 (6) 12 (67) 15 (83)
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Page 8 of 16carcinoma of the breast, we were able to detect biologi-
cally relevant interdependencies and heterogeneity lar-
gely reflecting the main intrinsic subtypes of the disease
and providing new data and insights into the breast can-
cer biology.
The design of our study enabled us to avoid signifi-
cant human impacts and assumptions while obtaining
the results: we performed an automated image analysis
with automated detection of tumour tissue of the ductal
carcinoma of the breast TMAs stained for 10 IHC mar-
kers, followed by factor analysis of the data set. In some
sense, our results represent an automated readout of the
IHC data in the TMAs. Factor analysis revealed latent
factors governing the interdependent variance of the
immunophenotype: being orthogonally independent by
definition, the factors can be seen as independent biolo-
gical processes standing behind the IHC profile variabil-
ity in the disease entities. We then produced integral
characteristics (factor scores) for individual patients and
tested their associations with main conventional cate-
gories of the breast ductal carcinoma.
The factors of the immunophenotype variance, estab-
lished in our study, are in line with the current knowl-
edge of breast cancer biology, however, new insights
emerge.
We found that major factor of the IHC profile varia-
tion in the ductal breast carcinoma was characterized by
a strong inverse relation between the expression of hor-
mone receptors (ER, PR, AR) along with anti-apoptotic
marker BCL2, on one side, and Ki67 (proliferation) and
HIF-1a (hypoxic stress, angiogenesis, see below), on the
other side. While the corresponding correlations were
detected by the pairwise correlation analysis (Table 2),
they were only moderate, true interdependencies being
obscured by multiple interactions in the dataset and dif-
ficult to interpret. We named the factor 1 the “i-Grade”
since its pattern reflected the interdependent variance of
the IHC markers known to represent the axis from
Figure 4 Association between the i-Grade and the histological grade (G). The bar chart represents the distribution of i-Grade-Low (grey)
and i-Grade-High (orange) tumours against the histological grade (G1, 2, and 3)
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Page 9 of 16aggressive (Ki67, HIF-1a) to more indolent (HR, BCL2)
behaviour of the disease [10]. In particular, biological
meaning of this factor includes the axis of anti-apoptotic
¬®proliferative effects that could be indicative of the
variance of the tumour growth behaviour. Importantly,
the anti-apoptotic effects were closely related to the
expression of HR, while proliferative effects were
paralleled by the marker of increased hypoxic stress and
angiogenesis (HIF-1a). Also, our interpretation of the
biological nature of the factor 1 (i-Grade) was further
confirmed by pronounced bimodal distribution of the
factor scores and strong associations with higher histo-
logical grade and the more aggressive intrinsic subtypes
(HER2 positive and Triple-negative).
The pattern of the factor 1 (i-Grade) reveals important
interactions between the HR, BCL2, Ki67, and HIF-1a.
Our data support the notion that BCL2 may be a useful
addition to the current scoring schemes as reported
recently by Dawson et al. [19]. Furthermore, a combined
mitotic/BCL2 or Ki67/BCL2 index reflects true biologi-
cal variation in breast cancer and may provide more
relevant prognostic information [14,20]. These latter
observations were based on a combination of semi-
quantitative scores of the two biomarkers; Ki67/BCL2
index was represented by subtraction of Ki67-BCL2
scores. As a matter of fact, factor 1 (i-Grade) scores
showed very strong correlation (r = 0.89, p< 0.0001,
data not shown) with the difference between Ki67 and
BCL2 expression (the percentage of Ki67 positive cells -
Figure 5 Representation of the factor score profiles of the intrinsic subtypes. The multiple line chart outlines the factor score profiles of
the intrinsic subtypes. The lines connect the mean values of the factor 1-5 scores obtained by one-way ANOVA for each intrinsic subtype as
explanatory variable.
Table 5 Rotated factor pattern of the immunothenotype
of the hormone receptor positive ductal carcinoma of the
breast
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5
ER -0.47598 -0.10090 -0.60245 -0.10337 -0.16151
PER -0.35541 -0.67714 -0.31955 0.29194 0.00229
AR -0.55499 -0.39729 -0.39127 0.24653 0.27274
BCL2 -0.48636 -0.34242 -0.31599 -0.38459 -0.01865
HER2 0.00251 0.87192 -0.15417 0.25187 0.08731
Ki67 -0.01734 -0.04969 0.82934 0.10271 -0.15723
p53 0.04843 0.05677 0.12929 0.88141 -0.12610
p16 -0.03786 0.06404 -0.09880 -0.12972 0.95100
HIF-1a 0.84950 0.06950 0.12918 -0.09585 0.05170
SATB1 0.87715 -0.08281 -0.20321 0.16228 -0.07999
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We therefore provide quantitative and multivariate ana-
lysis-based evidence supporting the suggested semi-
quantitative and empirical definition of the Ki67/BCL2
index [14]. In addition, our data suggest that inclusion
of HIF-1a into this integrated index of the disease
aggressiveness might bring more accuracy to this poten-
tial prognostic indicator.
Factor analysis, performed in the HR-positive sub-
group of cases (LA, LB, and LB HER2-positive),
extracted factor 3 (Ki67-ER) resembling the i-Grade by
its associations to the histological grade and the intrinsic
subtypes. The peculiarities of this “aggressiveness index”
in the HR-positive subpopulation of breast cancer
should be noted. First, the factor 3 (Ki67-ER) was no
longer the main source of variability and did not present
with bimodal distribution of the score values. This
change can be explained by the decreased variation of
Ki67 expression in the data set after exclusion of the
most proliferative subtypes (Triple-negative and HER2
positive). Second, the pattern of the factor 3 suggests
that Ki67/ER index rather than Ki67/BCL2 index might
be a more accurate measure of the aggressiveness of the
HR-positive disease. Or, at least, ER is tightly co-
expressed with BCL2 and therefore sufficient to be used
in combination with Ki67 in the HR-positive tumours.
Although clinical utility of BCL2 as an independent
prognostic marker has been suggested [19,21,22], this
notion has to undergo scrutiny of large prospective trials
and multivariate analyses. Third, although the Ki67-ER
was strongly associated with the histological grade and
intrinsic subtypes, it did attribute to the Ki67-ER-High
category 16 and 21% cases of the Grade 1 and Luminal
A tumours, respectively. This suggests that the com-
bined index may provide an added value to the conven-
tional categories securing against potential
misinterpretations in, at least, borderline cases. It has
been reported that Ki67 index can classify G2 breast
cancer into low and high risk subgroups [23]. It has
been shown that image analysis of Ki67 correlates
strongly with human evaluation, however, evaluation
bias is possible and the results are potentially dependent
Figure 6 Rotated factor pattern in the patients with hormone receptor positive breast ductal carcinoma: loadings of the factors 1 and
2 plotted. The loadings of the factor 1 (SATB1/HIF-1a - AR/ER/BCL2) and factor 2 (HER2-PR) plotted.
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Page 11 of 16Figure 7 Rotated factor pattern in the patients with hormone receptor positive breast ductal carcinoma: loadings of the factors 1 and
3 plotted. The loadings of the factor 1 (SATB1/HIF-1a - AR/ER/BCL2) and factor 2 (Ki67-ER) plotted.
Table 6 Associations between the factor scores and the conventional categories of the hormone receptor positive
ductal carcinoma of the breast
n i-IHC-High SATB1-High HER2-High p53-High p16-High
Number of patients 85
Age group n.s. p< 0.0015 n.s. p< 0.003 n.s.
Age < 55 year 39 12 (31) 12 (31) 22 (56) 30 (77) 20 (51)
Age > 55 year 46 12 (26) 30 (65) 18 (39) 21 (46) 25 (54)
Histological grade n.s. p< 0.2951 p< 0.0001 n.s. n.s.
1 19 6 (32) 7 (37) 3 (16) 8 (42) 9 (47)
2 38 10 (26) 22 (58) 14 (37) 25 (66) 22 (58)
3 28 8 (29) 13 (46) 23 (82) 18 (64) 14 (50)
T n.s. n.s. n.s. n.s. n.s.
1 49 13 (27) 28 (57) 22 (45) 32 (65) 23 (47)
2 36 11(31) 14 (39) 18 (50) 19 (53) 22 (61)
N n.s. n.s. n.s. n.s. n.s.
0 48 14 (29) 23 (48) 23 (48) 28 (58) 25 (52)
1 37 10(27) 19 (51) 17 (46) 23 (62) 20 (54)
Intrinsic subtype n.s. p< 0.0331 p< 0.0001 n.s. n.s.
Luminal A 43 13 (30) 19 (44) 7 (16) 21 (49) 22 (51)
Luminal B 27 7(26) 11 (41) 23 (85) 19 (70) 12 (44)
Luminal B HER2+ 15 4 (27) 12 (80) 10 (67) 11 (73) 11 (73)
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improved stratification based on combinatorial index
could be useful for better discrimination of Luminal A
and B subtypes, in particular, and decision on che-
motherapy. Interestingly, suggestions to develop specific
sets of prognostic IHC biomarkers in lymph node-nega-
tive and positive breast cancer subgroups [25] also can
be viewed as combinatorial approach, leading ultimately
to the concept of multimodal metamarkers of the dis-
ease [13].
HER2 expression was independent of other IHC para-
meters in the patients with ductal carcinoma, however,
in the HR-positive subset, HER2 “competed” mostly
with PR but not ER expression (Figure 6). This finding
is intriguing since the independent significance of ER
and PR (as well as BCL2) is not entirely clear because of
significant correlations between these biomarkers. Loss
of PR expression might indicate somewhat worse prog-
nosis compared to ER+/PR + tumours, whereas various
combinations of BCL2, p53, HER2 expression might
provide additional prognostic information as recently
reviewed by Rakha et al. [10]. In our study, we have
found relevant pairwise correlations between ER, PR,
and BCL2, however, factor analysis sheds the light into
their true interdependencies: in the context of ductal
breast carcinoma, we confirm that the HR and BCL2
expression is indeed highly inter-dependent and
governed by the same latent factor of variation which is
also characterized by inverse relation to Ki67 and HIF-
1a. In the context of HR-positive tumours, high ER
expression is seen in less proliferative (Ki67) cases,
whereas low PR expression may indicate higher HER2
expression. Therefore, differential ER and PR expression
may reflect differences in proliferative activity and HER2
expression of the HR-positive tumours; consequently,
carrying related prognostic information (if the continu-
ous increase of HER2 expression could be viewed as a
potential feature of more aggressive behaviour). As
noted already\, our analyses suggest that BCL2 corre-
lates closely with the expression of hormone receptors
(both in the whole group of patients and HR-positive
tumours) and does not carry an independent informa-
tion in the data sets.
Our study highlights the potential significance of rela-
tively new and less-explored biomarkers in breast can-
cer. SATB1, a genome organizer that recruits
chromatin-remodelling enzymes to regulate chromatin
structure and gene expression, has been recently impli-
cated to promote growth and metastasis of breast cancer
and indicate poor prognosis [26,27]. It was not con-
firmed by other studies and remains controversial as a
prognostic factor and a potential target for therapy
[28-31]. In particular, the expression levels of SATB1
mRNA in 2058 breast cancer samples were not related
Figure 8 Association between the Ki67-ER and the histological grade (G). The bar chart represents the distribution of Ki67-ER-Low (grey)
and Ki67-ER-High (orange) tumours against the histological grade (G1, 2, and 3).
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however, high SATB1 expression among ER positive
tumours showed beneficial prognosis; nevertheless, even
in ER positive cancer no independent prognostic value
in multivariate analysis with standard parameters was
observed [31]. In the study of Patani et al., high SATB1
expression levels were more often found in ER negative
tumour samples [27]. Our study presents first evidence
on correlation of IHC expression of SATB1 with ER and
other markers. The factor 1 (SATB1/HIF-1a-AR/ER/
BCL2) pattern in the HR-positive tumours revealed an
inverse relation between the two groups of markers with
the opposite factor loadings. Indeed, it is likely that the
prognostic effects of SATB1 can be caused by a possible
confounding effect of its inverse relation to ER expres-
sion [31]. Furthermore, we did not find any associations
of SATB1 expression with the histological grade or
other categories tested. Nevertheless, it is remarkable
that SATB1 was closely associated with HIF-1a in HR-
positive and the whole cohort of ductal carcinoma; the
factors with involvement of SATB1 and HIF-1a caused
a major portion of variation in both groups, especially,
in HR-positive tumours. This implies that SATB1 and
HIF-1a may be important markers of the disease,
whereas their biological and clinical significance remains
to be elucidated.
HIF-1a is broadly expressed in many human cancers
and frequently correlates with poor prognosis; it affects
many key aspects of tumour initiation, progression,
invasion, inflammatory cell recruitment and metastasis,
and represents an attractive target for anti-cancer thera-
pies as reviewed recently [32]. Yamamoto et al. [33]
reported on 171 cases of invasive breast cancer exam-
ined, nuclear HIF-1a expression was detected in 37%
cases (a cut-off of 5% was used as in previous study
[34]). HIF-1a was closely associated with indicators of
aggressive phenotype, such as high histological grade,
lymph node metastasis, large tumour size, high prolif-
eration rate, negativity of hormone receptors, HER2
positivity and increased VEGF expression; elevated levels
of HIF-1a expression were associated independently
with shorter disease-free and overall survival [33];
hypoxia and HIF-1a might be related to the worse prog-
nosis found in CD44 + CD24-/low positive breast
tumors [35]. Association of HIF-1a expression with
unfavourable prognosis in patients with breast cancer
has been demonstrated by previous studies [34,36,37]. In
o u rs t u d y ,w ec o n f i r mt h ea s s o c i a t i o no fH I F - 1 a and
Ki67 expression, both by pairwise correlation and simi-
lar factor loadings on the factor 1 (i-Grade) in the group
of ductal carcinoma. Also, the i-Grade scores were
strongly associated with histological grade, therefore,
confirming aggressive nature of HIF-1a and Ki67 (con-
firmed also by one-way ANOVA using HIF-1a and Ki67
as dependent variables, data not shown). However, inter-
pretation of the factor patterns in our analyses presents
some peculiarities. First, in the group of ductal carci-
n o m a ,w ef i n dt h a tH I F - 1 a participates in two factors:
factor 1 (i-Grade) along with Ki67 and factor 2 - along
with SATB1. In the group of ductal carcinoma, we find
that HIF-1a participates in two factors: factor 1 (i-
Grade) along with Ki67 and factor 2 - along with
SATB1. Second, in the group of HR-positive ductal car-
cinoma, HIF-1a participates in the most important fac-
tor 1 along with SATB1 providing factor loadings
opposite to those of AR, ER and BCL2, independently of
Ki67 expression (factor 3). This further supports the
notion that HIF-1a and SATB1 may convey important
biological messages other than the aggressiveness of the
disease reflected by Ki67 expression and histological
grade, at least in HR-positive disease.
Expression of p16 was governed by an independent
factor in our analyses and was remarkable for signifi-
cantly higher levels in the TN subtype compared to all
other intrinsic subtypes. We therefore support the
reports [38-41] on increased p16 expression in basal/tri-
ple-negative breast cancer also suggesting frequent inac-
tivation of the retinoblastoma tumour suppressor (Rb)
and up regulation of the cyclin-dependent kinase inhibi-
tor p16 in these tumours. Furthermore, down regulation
of p16 expression has been observed in some basal-like
breast cancer cell lines, suggesting that such cells can be
divided into two groups according to Rb and p16 status,
predictive of reduced chemo sensitivity in p16 depleted
cancers [42]. Interestingly, factor analysis performed in
t h es u b g r o u po f1 7p a t i e n t sw i t hT r i p l e - n e g a t i v e
tumours (data not shown), revealed strong association
of p16 expression with Ki67 and their strong inverse
relation to AR (but not ER or PR) expression. AR
expression has been reported as a marker of better
prognosis in Triple-negative breast cancer [43-45], how-
ever, our findings warn that this effect may be caused
by the confounding effect due to the inverse relation
between AR and Ki67 with p16. This data awaits confir-
mation on a larger set of patients.
In our study we extracted 5 factors from the dataset of
10 IHC markers, arriving to clinically and biologically
meaningful interpretation of the results. However, since
the results of factor analysis may be influenced the
number of factors extracted, defined by the investigator,
we have also tested the robustness of our results by
extracting 3 or 4 factors (not shown). The pattern of 4
factors extracted was largely the same, except p16 load-
ings moderately contributing to the i-Grade (-0.41) or
Ki67-ER (0.49), in all or HR-positive tumours respec-
tively. Similarly, extraction of 3 factors resulted in redis-
tribution of p53 loadings whereas the interactions of the
other markers remained essentially stable.
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sis of multiple IHC biomarkers measured by automated
DA is an efficient exploratory tool clarifying complex
interdependencies in the breast ductal carcinoma IHC
profiles. We find that a major factor of the aggressive
disease behaviour (i-Grade) is characterized by opposite
loadings of ER/PR/AR/BCL2 and Ki67/HIF-1a.T h ei -
Grade factor scores represent integral quantitative char-
acteristics that reveal bimodal distribution and are
strongly associated with the histological grade and rele-
vant intrinsic subtypes. In HR-positive tumours, the
aggressiveness of the tumour is best reflected by the
combination of Ki67 and ER, rather than Ki67 and
BCL2. These indices may provide additional risk stratifi-
cations for the currently used grading systems whereas
their clinical utility and cut-offs remain to be established
by analysis of clinical outcomes. Interestingly, we found
inverse relation between HER2 and PR expression in the
HR-positive tumours which, along with the inverse rela-
tion between Ki67 and ER, may shed the light into the
differential information conveyed by the ER and PR
expression. Remarkably, SATB1 along with HIF-1a
reflected the second major factor of variation in our
patients; furthermore, in the HR-positive group they
were inversely associated with the HR and BCL2 expres-
sion and represented the major factor contributing to
the variation in the IHC data set. However, this factor
was not associated with the clinicopathologic categories
studied. Biological meaning of this variation remains
unclear: HIF-1a and SATB1 may convey important bio-
logical messages other than the aggressiveness of the
disease reflected by Ki67 expression and histological
grade. Meanwhile, we support the notion that the sug-
gested prognostic significance of SATB1 may be related
to its inverse relation to the ER expression. Finally, our
analysis confirms high expression levels of p16 in Tri-
ple-negative tumours.
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